Roche Has Over Five Weight-Loss Companion Medicines, CEO Says
Roche Holding AG has more than five medicines that it could combine with weight-loss drugs, Chief Executive Officer Thomas Schinecker said, as the Swiss drugmaker tries to crack the pharmaceutical industry’s fastest-growing market. Combination therapy ...
Roche RHHBY announced an asset purchase agreement with clinical-stage biotechnology company Regor Therapeutics. Per the ...
Roche said on Monday that three early-stage obesity and diabetes drug candidates from its acquisition of Carmot Therapeutics ...
Roche Holding AG is aiming to deliver 20 new medicines to address diseases that rank among the biggest burdens to society ...
Roche is spending $850 million upfront to buy Regor Pharmaceuticals’ suite of next-generation CDK inhibitors as it doubles ...
The Temperature-Activated Generation of Signal (TAGS) technology was developed by Roche for its high-throughput PCR-based instruments.
In a report released today, Eric Le Berrigaud from Stifel Nicolaus maintained a Hold rating on Roche Holding AG (RHHVF – Research ...
The the Swiss drugmaker will face off in the obesity area with leaders Novo Nordisk A/S and Indianapolis-based Eli Lilly and ...
Meanwhile, the acquisition of AntlerA, which Roche called a leader in Wnt signaling, gives the pharma ownership of a library ...
(RTTNews) - Swiss drug major Roche Group (RHHBY), at its Pharma Day 2024, said it expects sales momentum to continue into 2025, with strong growth by both divisions of Pharma and Diagnostics. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback